CUE RSI Strategy
Today’s Change (Apr 20, 2026)
—
A symphony is an automated trading strategy — Learn more about symphonies here
About
Daily rule for Cue Biopharma: buy CUE only when a simple momentum score (14‑day RSI) says it’s oversold (<30); otherwise hold BIL (short‑term T‑bill ETF). Goal: buy sharp dips and sit in cash otherwise. Concentrated, high risk.
Each day the plan checks a simple 0–100 “oversold/overbought” score (14‑day RSI) on Cue Biopharma (CUE). If the score is below 30—meaning the stock has fallen fast—it buys CUE. If it’s 30 or higher, it holds BIL, a short‑term U.S. T‑bill ETF that acts like cash.
Rules-based biotech dip-capture with cash buffer. A potential diversifier to SPY, offering downside discipline and exposure to mean-reversion. Note: out-of-sample shows negative returns and larger drawdowns, so best as a satellite, not core equity.
1M
3M
6M
YTD
1Y
3Y
Max
Performance
Compared to selected benchmarks
| Alpha | Beta | R2 | R | |
|---|---|---|---|---|
| 0.23 | 0.14 | 0.01 | 0.08 |
Performance Metrics
| Cumulative Return | Annualized Return | Trailing 1M Return | Trailing 3M Return | Sharpe Ratio | |
|---|---|---|---|---|---|
| 184.81% | 13.59% | 6.16% | 5.09% | 0.76 | |
| 378.27% | 20.99% | 35.42% | 36.16% | 0.69 |
Initial Investment
$10,000.00
Final Value
$47,827.23Regulatory Fees
$181.71
Total Slippage
$369.21
Invest in this strategy
OOS Start Date
Nov 7, 2024
Trading Setting
Daily
Type
Stocks
Category
Single-stock biotech, rsi mean-reversion, rules-based tactical, daily rebalance, cash/t-bills
Tickers in this symphonyThis symphony trades 2 assets in total
Ticker
Type
BIL
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
Stocks
CUE
Cue Biopharma, Inc.
Stocks